<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Losartan</id>
	<title>Losartan - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Losartan"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Losartan&amp;action=history"/>
	<updated>2026-05-01T05:14:17Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Losartan&amp;diff=5539475&amp;oldid=prev</id>
		<title>Prab: Text replacement - &quot;Category:Wikipedia medicine articles ready to translate&quot; to &quot;&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Losartan&amp;diff=5539475&amp;oldid=prev"/>
		<updated>2024-04-07T11:00:50Z</updated>

		<summary type="html">&lt;p&gt;Text replacement - &amp;quot;&lt;a href=&quot;/index.php?title=Category:Wikipedia_medicine_articles_ready_to_translate&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;Category:Wikipedia medicine articles ready to translate (page does not exist)&quot;&gt;Category:Wikipedia medicine articles ready to translate&lt;/a&gt;&amp;quot; to &amp;quot;&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{intro}}&lt;br /&gt;
[[File:Losartan_structure.svg|Losartan_structure|thumb]]&lt;br /&gt;
Losartan is an angiotensin II receptor blocker used in the therapy of hypertension and diabetic nephropathy.  &lt;br /&gt;
{{livtox}}&lt;br /&gt;
Losartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.&lt;br /&gt;
{{moa}}&lt;br /&gt;
Losartan (loe sar&amp;#039; tan) was the first angiotensin II receptor blocker (ARB) to be approved for use in the United States and is still widely used for therapy of hypertension.  Losartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II and thus accounts for its antihypertensive activity.  &lt;br /&gt;
{{fda}}&lt;br /&gt;
Losartan was approved for use in the United States in 1995 and current indications include hypertension as well as prevention of progression of diabetic nephropathy, and decrease in risk of stroke in patients with hypertension and left ventricular hypertrophy.  &lt;br /&gt;
{{dose}}&lt;br /&gt;
Losartan is available in 25, 50 and 100 mg tablets in generic forms and under the trade name Cozaar.  Fixed dose combinations with hydrochlorothiazide are also available (Hyzaar and others). The typical dose of losartan in adults in 50 to 100 mg in one or two divided doses daily and it is used long term.  &lt;br /&gt;
{{se}}&lt;br /&gt;
Side effects are uncommon, but can include headache, dizziness, fatigue, cough, gastrointestinal upset, and fetal toxicity.  Chronic therapy with losartan has been implicated in rare instances of severe sprue-like enteropathy that typically presents after months or years of therapy with diarrhea, weight loss, and abdominal discomfort.  Intestinal biopsy that shows villous fattening and atrophy, similar to celiac disease.  However, the diarrhea does not improve with a gluten-free diet, but does resolve promptly with stopping the losartan.  This adverse effect is most common with olmesartan.&lt;br /&gt;
==Contraindications==&lt;br /&gt;
Losartan should not be used in the following situations:&lt;br /&gt;
&lt;br /&gt;
* Known hypersensitivity to losartan or any components of the formulation&lt;br /&gt;
* Pregnancy: Losartan is classified as FDA pregnancy category D and can cause fetal harm or death.&lt;br /&gt;
* Concomitant use of [[aliskiren]] in patients with diabetes or kidney impairment&lt;br /&gt;
==Drug interactions==&lt;br /&gt;
Losartan may interact with other medications, including:&lt;br /&gt;
&lt;br /&gt;
* [[Potassium-sparing diuretics]] or [[potassium supplements]]: Increased risk of hyperkalemia.&lt;br /&gt;
* [[Nonsteroidal anti-inflammatory drugs]] (NSAIDs): Reduced antihypertensive effect and increased risk of kidney dysfunction.&lt;br /&gt;
* [[Lithium]]: Increased risk of lithium toxicity.&lt;br /&gt;
==See also==&lt;br /&gt;
* [[Angiotensin II receptor antagonist]]&lt;br /&gt;
* [[Hypertension]]&lt;br /&gt;
* [[Diabetic kidney disease]]&lt;br /&gt;
* [[Heart failure]]&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{Merck&amp;amp;Co}}&lt;br /&gt;
{{Angiotensin II receptor antagonists}}&lt;br /&gt;
{{Angiotensin receptor modulators}}&lt;br /&gt;
{{Portal bar | Medicine}}&lt;br /&gt;
[[Category:Angiotensin II receptor antagonists]]&lt;br /&gt;
[[Category:Biphenyls]]&lt;br /&gt;
[[Category:Chloroarenes]]&lt;br /&gt;
[[Category:Merck &amp;amp; Co. brands]]&lt;br /&gt;
[[Category:Imidazoles]]&lt;br /&gt;
[[Category:Primary alcohols]]&lt;br /&gt;
&lt;br /&gt;
[[Category:Tetrazoles]]&lt;br /&gt;
[[Category:World Health Organization essential medicines]]&lt;br /&gt;
[[Category:Orphan drugs]]&lt;br /&gt;
[[Category:Butyl compounds]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>